Overview

A Study of LUMIGAN® RC in the Clinical Setting

Status:
Completed

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

Summary

This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.

Phase:

Phase 4

Details

Lead Sponsor:

Allergan

Treatments:

Bimatoprost